Seres Therapeutics, Inc , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.
infoSeres Therapeutics is a small cap stock with a total market cap of 456.41M.
infoThey trade on the NASDAQ and had their IPO 8 years and 1 month ago.
infoSeres Therapeutics currently employs 431 people.
infoAs of Wednesday, Aug 23 2023, Seres Therapeutics’s share price is $3.56.
News Relating to Seres Therapeutics
Zacks Investment Research
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
Tuesday Aug 08 2023 at 09:55
Seres Therapeutics (MCRB) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to loss of $0.70 per share a year ago.
PennyStocks
Best Penny Stocks To Buy? 5 With Big News This Week
Wednesday Jun 07 2023 at 11:16
Are you searching for some of the best penny stocks to buy now? I’m sure that if you’re reading this article, that’s something at the top of your mind.
Business Wire
Seres Therapeutics to Present at Jefferies Healthcare Conference
Friday Jun 02 2023 at 07:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:00 a.m. ET in New York City. An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will b.
Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Tuesday May 09 2023 at 09:57
Seres Therapeutics (MCRB) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.61 per share a year ago.
Seeking Alpha
Seres Gets FDA Approval And The Share Price Goes Down!
Wednesday May 03 2023 at 10:29
Biotech investing is a wild ride but share prices falling after FDA approval, as has just happened to Seres Therapeutics VOWST product, is pretty weird. On April 26, Seres achieved FDA approval for VOWST (formerly known as SER-109). This is the first FDA approval for an oral microbiomic product, a big deal for the microbiome.
The Motley Fool
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
Thursday Apr 20 2023 at 09:45
Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.
Zacks Investment Research
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
Friday Apr 14 2023 at 06:51
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Wednesday Mar 22 2023 at 05:21
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seeking Alpha
Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call Transcript
Tuesday Mar 07 2023 at 14:05
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Carlo Tanzi – IR Officer Eric Shaff – President, CEO & Director Teresa Young – EVP and Chief Commercial & Strategy Officer Lisa von Moltke – EVP & Chief Medical Officer David Arkowitz – EVP, CFO & Head, Business Development David Ege – EVP & CTO Matthew Henn – EVP & Chief Scientific Officer Conference Call Participants Mark Breidenbach – Oppenheimer John Newman – Canaccord Genuity Edward Tenthoff – Piper Sandler & Co. Stephen Sloan – Goldman Sachs Group John Bohnsack – TD Cowen Operator Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. [Operator Instructions].
Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
Tuesday Mar 07 2023 at 09:47
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Seres Therapeutics: FDA Approval Straight Ahead
Monday Feb 06 2023 at 14:42
Today, we take a look at microbiome therapeutic developer Seres Therapeutics, Inc. Seres Therapeutics appears headed to its first FDA approval and has a strategic partnership with Nestlé S.A. around this endeavor.
Seeking Alpha
The Clock Is Ticking For Seres Therapeutics: I’m Not Afraid
Sunday Feb 05 2023 at 02:34
April 26 is FDA decision day for SER-109, the Seres microbiome treatment for recurrent C. difficile infection. Finch Therapeutics gives up on Phase 3 trial for C. difficile recurrence; lays off 95% of staff.
Business Wire
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
Tuesday Nov 22 2022 at 16:01
CAMBRIDGE, Mass.–( BUSINESS WIRE )–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.
Seeking Alpha
Seres Gets Closer To Good Times
Thursday Nov 10 2022 at 11:34
After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109.
Seeking Alpha
Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript
Wednesday Nov 02 2022 at 14:06
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Carlo Tanzi – Head of Investor Relations Eric Shaff – President & Chief Executive Officer Lisa von Moltke – Chief Medical Officer Matthew Henn – Chief Scientific Officer David Arkowitz – Chief Financial Officer Teresa Young – Chief Commercial & Strategy Officer Conference Call Participants Peyton Bohnsack – Cowen Ted Tenthoff – Piper Sandler Mark Breidenbach – Oppenheimer John Newman – Canaccord Operator Good morning. My name is Colby and I will be your conference operator today.
Business Wire
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
Thursday Oct 27 2022 at 07:00
CAMBRIDGE, Mass.
Business Wire
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
Wednesday Oct 12 2022 at 07:00
CAMBRIDGE, Mass.
Seeking Alpha
Seres Therapeutics: What The Market Is Missing
Friday Aug 19 2022 at 07:00
Seres Therapeutics was founded in 2010 at a time when the Human Microbiome Project was “hot”. So Seres was there when microbiomics began to get serious. Nestle Health Science has been an early investor and concluded a major deal on marketing rights in early 2016. The first product, SER-109, is being readied for market.
Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
Wednesday Aug 03 2022 at 09:47
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Seres Therapeutics: The Good And The Challenging
Tuesday Jul 12 2022 at 13:42
Seres’ $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market – how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence?
Seeking Alpha
Seres Therapeutics: The Pipeline Is The Problem
Friday Jun 10 2022 at 11:41
SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy.
Seeking Alpha
Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens
Thursday Jun 09 2022 at 12:08
Seres Therapeutics reports new data concerning safety and effectiveness of SER-109 for treating recurrent C.difficile infection. This completes Seres package for BLA (Biologics License Application) to the FDA.
Benzinga
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug
Tuesday Jun 07 2022 at 12:29
Seres Therapeutics Inc (NASDAQ: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI).
Seeking Alpha
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results – Earnings Call Transcript
Wednesday May 04 2022 at 13:12
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Carlo Tanzi – Head of Investor Relations Eric Shaff – President and Chief Executive Officer Lisa von Moltke – Chief Medical Officer Matthew Henn – Chief Scientific Officer David Arkowitz – Chief Financial Officer Terri Young – Chief Commercial and Strategy Officer David Ege – Chief Technology Officer Conference Call Participants Mark Breidenbach – Oppenheimer Peyton Bohnsack – Cowen John Newman – Canaccord Chris Howerton – Jeffries Vernon Bernardino – H.C. Wainwright Operator Welcome to Seres Therapeutics First Quarter 2022 Financial Results Conference Call.
Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Wednesday May 04 2022 at 09:47
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Proactive Investors
Destiny Pharma undervalued compared to peers, suggests finnCap
Tuesday Apr 12 2022 at 07:49
Destiny Pharma’s 29021 year-end cash of £4.65mln together with a £6.5mln fundraise in March 2022 provides a funding runway into mid-2023, says house broker finnCap. “With several companies active in the NTCD-M3 data room, we look forward to the company securing a partner to co-fund the Phase 3 trial.
Seeking Alpha
Seres Therapeutics Is Playing A Long Game
Sunday Mar 06 2022 at 07:00
Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million.
Seeking Alpha
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results – Earnings Call Transcript
Tuesday Mar 01 2022 at 15:39
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results – Earnings Call Transcript
Zacks Investment Research
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates
Tuesday Mar 01 2022 at 10:44
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Forbes
Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A Stellar 77% Surge In A Month?
Thursday Dec 02 2021 at 07:00
The stock price of Seres Therapeutics, a small late stage clinical biotechnology company with a market cap of around $1 billion, is up a whopping 77% in a month, while it is up 17% over the last week. There were multiple positive developments that supported the stock price growth for Seres.
Seres Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Seres Therapeutics’s Altman Z-score is -2.77 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Seres Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Seres Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Seres Therapeutics’s Income Quality of 1.2 is greater than its Industry Group of 0.69 (73.9% greater)
Seres Therapeutics’s Income Quality of 1.2 is greater than its Major Industry Group of 0.71 (69.0% greater)
Seres Therapeutics’s Income Quality of 1.2 is greater than its Sector of 0.75 (60.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Seres Therapeutics’s Current Ratio of 3.23 is lower than its Industry Group of 4.76 (-32.1% lower)
Seres Therapeutics’s Current Ratio of 3.23 is lower than its Major Industry Group of 4.32 (-25.2% lower)
Seres Therapeutics’s Current Ratio of 3.23 is greater than its Sector of 2.6 (24.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-2.94 & -1.27)
Cannot compare a negative PE Ratio (-2.94 & -1.1)
Cannot compare a negative PE Ratio (-2.94 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Seres Therapeutics’s PB Ratio of 20.18 is greater than its Industry Group of 1.34 (1406.0% greater)
Seres Therapeutics’s PB Ratio of 20.18 is greater than its Major Industry Group of 1.4 (1341.4% greater)
Seres Therapeutics’s PB Ratio of 20.18 is greater than its Sector of 1.62 (1145.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Seres Therapeutics’s ROE of -6.87 is lower than its Industry Group of -0.44 (-1461.4% lower)
Seres Therapeutics’s ROE of -6.87 is lower than its Major Industry Group of -0.38 (-1707.9% lower)
Seres Therapeutics’s ROE of -6.87 is lower than its Sector of -0.03 (-22800.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Seres Therapeutics’s ROCE of -0.45 is in line with its Industry Group of -0.42 (-7.1% lower)
Seres Therapeutics’s ROCE of -0.45 is lower than its Major Industry Group of -0.37 (-21.6% lower)
Seres Therapeutics’s ROCE of -0.45 is lower than its Sector of -0.04 (-1025.0% lower)
Derived from SEC.GOV filing dataopen_in_new